FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1974949955> ?p ?o ?g. }

• W1974949955 endingPage "S221" @default.
• W1974949955 startingPage "S220" @default.
• W1974949955 abstract "EBV lymphomas (EBV-L) arising post HSCT that persist or recur following Rituxan therapy are often fatal. We analyzed treatment with EBV-specific T-cells (EBV-CTL) in 22 patients (pts) who developed EBV-L following HLA-matched (N=8) or non-identical N=11 T cell depleted (N=17) or unmodified (N=3) HSCT or cord blood grafts (N=3). All pts had clinical and radiologic evidence of rapidly growing tumors of Waldeyer's ring and/or intestines, liver, lung or CNS and rising blood levels of EBV DNA. Biopsies showed B cell, EBV+ lymphoma in 20 pts that were monoclonal (12/12 tested) and usually of donor origin (11/12 tested). Of 22 pts, 14 had failed (N=10) or recurred (N=4) following Rituxan treatment. EBV-CTL were grown from donor T-cells sensitized with autologous EBVBLCL transformed by EBV strain B95.8 (B95.8 EBVBLCL) and tested for specificity, lack of alloreactivity and sterility. Treatment included 3 weekly infusions of EBV-CTL (106 T cells/kg/Dose). Tumor responses, EBV DNA levels and quantitations of tetramer+, IFNγ+ EBV-specific T-cells and EBV CTLp by limiting dilution analysis (LDA) were monitored. Infusions were well tolerated; no pt developed GVHD. Of the 22 pts, 3 died too early to be evaluated (<10 days). Of 6 pts primarily treated with EBV-CTL, 5 (83%) achieved CR, versus 7/13 (53%) who failed Rituxan. The CR rate was similar in pts on no immunosuppressives or on Sirolimus or Calcineurin inhibitors alone (75% with; 67% without), but was lower for pts on steroids for GVHD or cerebral edema (33%) than for pts off steroids (69%). Pts with single sites of disease fared better than pts with multiple sites (75% vs. 42% CR). However, all sites of disease, including CNS, were comparably responsive to therapy. CTLp frequencies rose 10-200 fold by 2-3 weeks post infusion in pts achieving CR and were temporally associated with disease regression and clearance of EBV DNA. Such increases were not seen in any pt with PD. EBV CTLs inducing CRs in 8 pts studied lysed both B95.8 EBVBLCL and spontaneous EBV+ BLCL transformants (S-EBV BLCL) isolated from the pt's blood or involved tissues; EBV CTL given to 3 non-responders on no immunosuppression lysed B95.8+ BLCL, but not S-EBVBLCL of donor origin isolated from the pt. While EBVCTL can induce durable remissions of EBV lymphoma post HSCT, efficacy may be compromised in Rituxan refractory disease, by ongoing steroid treatment or by failure of the EBVCTL to recognize the endogenous EBV the pt's lymphoma." @default.
• W1974949955 created "2016-06-24" @default.
• W1974949955 creator A5003197311 @default.
• W1974949955 creator A5028656735 @default.
• W1974949955 creator A5031349996 @default.
• W1974949955 creator A5036520753 @default.
• W1974949955 creator A5043966208 @default.
• W1974949955 creator A5045747432 @default.
• W1974949955 creator A5052956899 @default.
• W1974949955 creator A5053265843 @default.
• W1974949955 creator A5058476408 @default.
• W1974949955 creator A5067712388 @default.
• W1974949955 creator A5071873190 @default.
• W1974949955 creator A5076979099 @default.
• W1974949955 creator A5079056173 @default.
• W1974949955 creator A5079103223 @default.
• W1974949955 creator A5085595407 @default.
• W1974949955 creator A5086622778 @default.
• W1974949955 date "2010-02-01" @default.
• W1974949955 modified "2023-09-27" @default.
• W1974949955 title "Adoptive Transfer Of EBV Specific T-Cells For Treatment Of Primary And Rituxan Resistant EBV Lymphomas Following Allogeneic Stem Cell Transplants (HSCT): Clinical, Viral And Immunologic Corelates" @default.
• W1974949955 doi "https://doi.org/10.1016/j.bbmt.2009.12.205" @default.
• W1974949955 hasPublicationYear "2010" @default.
• W1974949955 type Work @default.
• W1974949955 sameAs 1974949955 @default.
• W1974949955 citedByCount "0" @default.
• W1974949955 crossrefType "journal-article" @default.
• W1974949955 hasAuthorship W1974949955A5003197311 @default.
• W1974949955 hasAuthorship W1974949955A5028656735 @default.
• W1974949955 hasAuthorship W1974949955A5031349996 @default.
• W1974949955 hasAuthorship W1974949955A5036520753 @default.
• W1974949955 hasAuthorship W1974949955A5043966208 @default.
• W1974949955 hasAuthorship W1974949955A5045747432 @default.
• W1974949955 hasAuthorship W1974949955A5052956899 @default.
• W1974949955 hasAuthorship W1974949955A5053265843 @default.
• W1974949955 hasAuthorship W1974949955A5058476408 @default.
• W1974949955 hasAuthorship W1974949955A5067712388 @default.
• W1974949955 hasAuthorship W1974949955A5071873190 @default.
• W1974949955 hasAuthorship W1974949955A5076979099 @default.
• W1974949955 hasAuthorship W1974949955A5079056173 @default.
• W1974949955 hasAuthorship W1974949955A5079103223 @default.
• W1974949955 hasAuthorship W1974949955A5085595407 @default.
• W1974949955 hasAuthorship W1974949955A5086622778 @default.
• W1974949955 hasBestOaLocation W19749499551 @default.
• W1974949955 hasConcept C147969180 @default.
• W1974949955 hasConcept C167672396 @default.
• W1974949955 hasConcept C203014093 @default.
• W1974949955 hasConcept C2522874641 @default.
• W1974949955 hasConcept C2776090121 @default.
• W1974949955 hasConcept C2779338263 @default.
• W1974949955 hasConcept C2781375147 @default.
• W1974949955 hasConcept C71924100 @default.
• W1974949955 hasConcept C8891405 @default.
• W1974949955 hasConceptScore W1974949955C147969180 @default.
• W1974949955 hasConceptScore W1974949955C167672396 @default.
• W1974949955 hasConceptScore W1974949955C203014093 @default.
• W1974949955 hasConceptScore W1974949955C2522874641 @default.
• W1974949955 hasConceptScore W1974949955C2776090121 @default.
• W1974949955 hasConceptScore W1974949955C2779338263 @default.
• W1974949955 hasConceptScore W1974949955C2781375147 @default.
• W1974949955 hasConceptScore W1974949955C71924100 @default.
• W1974949955 hasConceptScore W1974949955C8891405 @default.
• W1974949955 hasIssue "2" @default.
• W1974949955 hasLocation W19749499551 @default.
• W1974949955 hasOpenAccess W1974949955 @default.
• W1974949955 hasPrimaryLocation W19749499551 @default.
• W1974949955 hasRelatedWork W1512641202 @default.
• W1974949955 hasRelatedWork W2018288464 @default.
• W1974949955 hasRelatedWork W2019916283 @default.
• W1974949955 hasRelatedWork W2042712871 @default.
• W1974949955 hasRelatedWork W2054101033 @default.
• W1974949955 hasRelatedWork W2068970201 @default.
• W1974949955 hasRelatedWork W2123097534 @default.
• W1974949955 hasRelatedWork W2321237021 @default.
• W1974949955 hasRelatedWork W2577275033 @default.
• W1974949955 hasRelatedWork W2787171899 @default.
• W1974949955 hasVolume "16" @default.
• W1974949955 isParatext "false" @default.
• W1974949955 isRetracted "false" @default.
• W1974949955 magId "1974949955" @default.
• W1974949955 workType "article" @default.